NEW YORK, July 30 - NeoGenesis Pharmaceuticals said today it will apply its NeoMorph compound library and ALIS ligand-identification technology in a drug-discovery deal with Pharmacia.
The deal calls for NeoGenesis to use NeoMorph and ALIS on certain proteins supplied by Pharmacia in the hopes of discovering small-molecule compounds that bind to them.
In exchange, NeoGenesis, of Cambridge, Mass., will receive undisclosed upfront payments, milestones, and royalties pegged to the success of the collaboration.
NeoGenesis said Pharmacia will oversee the management of any drug leads that arise from the research.
Click here or more information.